Search research articles
Contact Us
Filters
Showing results (31-40 of 105) with videos related to
Page
of 11
Sort By:
Future Oncology (London, England)
|
January 19, 2021
Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review
Cedric Pobel, Edouard Auclin, Adrien Procureur, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
May 27, 2017
A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer
Alicja Puszkiel, Alain Plé, Olivier Huillard, et al.
Therapeutic Advances in Medical Oncology
|
January 25, 2021
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
Pernelle Lavaud, Clément Dumont, Constance Thibault, et al.
Nature Reviews. Urology
|
January 31, 2024
Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases
Elisabeth Grobet-Jeandin, Louis Lenfant, Ugo Pinar, et al.
Expert Review of Anticancer Therapy
|
December 15, 2016
Sunitinib in kidney cancer: 10 years of experience and development
Elise Nassif, Constance Thibault, Yann Vano, et al.
Bulletin Du Cancer
|
July 5, 2020
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer
Nicolas Epaillard, Audrey Simonaggio, Reza Elaidi, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
January 30, 2019
Pharmaceutical interventions to improve safety of chemotherapy-treated cancer patients: A cross-sectional study
Johanne Daupin, Germain Perrin, Chloe Lhermitte-Pastor, et al.
Bulletin Du Cancer
|
March 11, 2023
[Collecting duct carcinoma and renal medullary carcinoma in the age of new therapies]
Zoé Guillaume, Yves Allory, Edouard Auclin, et al.
World Journal of Urology
|
September 12, 2023
Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756)
Giorgio Calleris, Morgan Rouprêt, Thomas Seisen, et al.
ESMO Open
|
August 2, 2017
Patient-reported tolerability of adverse events in phase 1 trials
Clémence Henon, Delphine Lissa, Xavier Paoletti, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 105) with videos related to
Sort By:
Page
of 11
Future Oncology (London, England)
|
January 19, 2021
Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review
Cedric Pobel, Edouard Auclin, Adrien Procureur, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
May 27, 2017
A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer
Alicja Puszkiel, Alain Plé, Olivier Huillard, et al.
Therapeutic Advances in Medical Oncology
|
January 25, 2021
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
Pernelle Lavaud, Clément Dumont, Constance Thibault, et al.
Nature Reviews. Urology
|
January 31, 2024
Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases
Elisabeth Grobet-Jeandin, Louis Lenfant, Ugo Pinar, et al.
Expert Review of Anticancer Therapy
|
December 15, 2016
Sunitinib in kidney cancer: 10 years of experience and development
Elise Nassif, Constance Thibault, Yann Vano, et al.
Bulletin Du Cancer
|
July 5, 2020
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer
Nicolas Epaillard, Audrey Simonaggio, Reza Elaidi, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
January 30, 2019
Pharmaceutical interventions to improve safety of chemotherapy-treated cancer patients: A cross-sectional study
Johanne Daupin, Germain Perrin, Chloe Lhermitte-Pastor, et al.
Bulletin Du Cancer
|
March 11, 2023
[Collecting duct carcinoma and renal medullary carcinoma in the age of new therapies]
Zoé Guillaume, Yves Allory, Edouard Auclin, et al.
World Journal of Urology
|
September 12, 2023
Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756)
Giorgio Calleris, Morgan Rouprêt, Thomas Seisen, et al.
ESMO Open
|
August 2, 2017
Patient-reported tolerability of adverse events in phase 1 trials
Clémence Henon, Delphine Lissa, Xavier Paoletti, et al.
Page
of 11